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1. Introduction 
Lung cancer is the leading cause of cancer-related death worldwide. Surgical resection is the 
treatment of choice for early-stage non-small cell lung cancer (NSCLC).1,2 Five-year survival in 
patients with resected stage I NSCLC ranges between 55% and 80%.3-6 Tumor recurrence is the 
most common cause of death, and thus the main obstacle for long-term survival after 
resection.4-10 The postoperative recurrence rates in stage I NSCLC range between 22% to 38%.4-8   
The incidence of local or regional recurrence in stage I NSCLC after surgical resection has been 
reported between 7% to 15%,4-6 while distant metastasis been reported between 14% and 23%.4-8 
Post-recurrence survival in resected stage I NSCLC is poor.7,10-12 
The fifth edition of the TNM staging system for lung cancer was published in 1997, and 
stage I NSCLC was subdivided into IA (T1N0M0, tumor size ≤ 3 cm) and IB (T2N0M0, 
tumor size > 3 cm).3 In addition to tumor size greater than 3 cm, the T2 descriptor also 
includes tumors that invade the visceral pleura regardless of size, tumors that involve the 
main bronchus ≥ 2 cm distal to the carina, and tumors that result in associated atelectasis 
and obstructive pneumonitis that extends to the hilar region but does not involve the entire 
lung radiographically.3 In the sixth edition of the TNM classification (TNM 6)13 for lung 
cancer published in 2002, no change was made to the previous edition.3 The seventh edition 
of the TNM classification (TNM 7) for lung cancer has been published in 2009.14,15 The 
changes to the TNM 6 for lung cancer were based upon the proposals from the International 
Association for the Study of Lung Cancer (IASLC). In the seventh edition, T1 descriptor has 
been classified into T1a (≤ 2 cm) and T1b (> 2 to ≤ 3 cm), while size-based T2 descriptor has 
been classified into T2a (> 3 to ≤ 5 cm), T2b (> 5 to ≤ 7 cm), and T3 (> 7 cm).16 Stage I NSCLC 
was subdivided into IA (T1aN0M0, T1bN0M0) and IB (T2aN0M0).17 T2bN0M0 was 
reclassified as stage IIA.17 
This review focuses on recurrence patterns of stage I NSCLC after surgical resection, 
survival after recurrence, and its prognostic factors. Predictors for local recurrence and 
distant metastasis are analyzed and discussed separately. Recent reports in the literature 
aiming at recurrence patterns and survival in stage I NSCLC (TNM 7) were also reviewed 
and included. 
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2. Prognostic factors for stage I NSCLC 
The prognostic factors of stage I NSCLC (TNM 6) have been widely reported in the 
literature.4-6,18,19 Martini et al4 reported that T2 status and sublobar resection were the 
prognostic factors for poor overall survival in resected stage I NSCLC. Harpole et all5 
reported that presence of symptoms, vascular invasion, visceral pleural invasion and tumor 
size greater than 3 cm were the factors affecting overall survival in resected stage I NSCLC. 
Sawyer et al18 reported that factors predicting poor overall survival included fewer than 15 
lymph nodes dissected and tumor size greater than 3 cm. Varlotto et al19 also reported that 
lymphadenectomy was associated with improved overall survival and disease-free survival 
in resected stage I NSCLC. Many other reports also demonstrated the prognostic value of 
tumor size in stage I NSCLC.6,20 The number of mediastinal lymph nodes 
dissected/sampled alternatively represents the quality of lymphadenectomy and affects the 
survival rate for patients with resected stage I NSCLC.19,21 Our previous studies21,22 also 
showed that number of mediastinal lymph nodes dissected/sampled was a predictor of 
survival in stage I NSCLC. Cigarette smoking has been shown to be another prognostic 
factor in patients with NSCLC in the literature.23-26 Hanagiri et al23 reported that smoking 
was a significant postoperative prognostic factor in patients with NSCLC. Bryant et al24 
reported that 5-year survival rate was significantly better for never smokers compared to 
smokers in stage I NSCLC (TNM 6).  
Only few studies reported the prognostic factors of stage I NSCLC (TNM 7).25-28 In the 
report by Maeda et al, 27 5-year overall survival rates for stage IA and IB (TNM 7) were 
89.9% and 72.3%, respectively. They also demonstrated that older age, intratumoral vascular 
invasion, and visceral pleural invasion were poor prognostic factors in stage IB NSCLC.27 In 
the report by Maeda et al,27 5-year disease-specific survival rates for stage IA and IB NSCLC 
(TNM 7) were 93.1% and 72.3%, respectively. They also demonstrated that intratumoral 
vascular invasion and visceral pleural invasion were poor prognostic factors for cancer-
specific survival in stage IB NSCLC.27 Maeda et al25 reported that overall survival and 
recurrence-free survival in never smokers were significant better than those of ever smokers 
in patients with stage I NSCLC (TNM 7). Maeda et al26 also discovered that a greater 
smoking extent was associated with the presence of solid components in stage I lung 
adenocarcinoma, which may have more aggressive biological features resulting in poorer 
outcomes. 
3. Recurrence patterns 
For stage I NSCLC (TNM 6), Martini et al4 reported that the 2- and 5-year recurrence-free 
rates were 84% and 76%, respectively. Sixty percent of patients developed recurrence within 
the first 2 years after operation. Sawyer et al18 reported that 5-year of local recurrence-free 
and distant metastasis-free rates were 85% and 83%, respectively, in patients with resected 
stage I NSCLC. In the study by Varlotto et al 29 regarding tumor recurrence in patients with 
resected NSCLC (including 82% of patients with stage I NSCLC), the 2- and 5-year local 
recurrence-free rates were 84% and 68%, respectively. The 2- and 5-year distant metastasis-
free rates were 87% and 79%, respectively.  
Martini et al4 reported the overall incidence of recurrence in patients with resected stage I 
NSCLC was 27% (local or regional 7%, systemic 20%). In the study by Harpole et al,5 the 
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initial location of recurrence of stage I NSCLC after surgical resection was at a distant site in 
19%, within the ipsilateral hemithorax in 11% or at both locations in 6% of patients. Distant 
recurrence rates between 14% to 23% in stage I NSCLC after surgical resection have also 
been reported in the literature.6-8 Our studies11,12 demonstrated that overall incidence of 
recurrence was 31.0% (distant only in 17.8%, local only in 7.9%, local and distant in 5.3%) in 
stage I NSCLC after surgical resection. The patterns of local recurrence included local only 
in 60.2%, local with distant in 15.4%, local before distant in 19.5% and distant before local in 
4.9% of patients. Approximately 78% of patients with local recurrence occurred within the 
first 2 years after operation. We also showed that approximately 84% of patients with distant 
metastases occurred within the first 2 years after operation. A major proportion of patients 
(62%) died within one year after distant metastasis.  
Most distant metastases appear as multiple foci in multiple organs after treatment of 
original cancer.30 Martini et al4 reported that the most common site of distant metastasis in 
patients with resected stage I NSCLC was the brain. Yoshino et al31 demonstrated that 
pulmonary metastasis was most common in NSCLC patients with recurrence at distant 
organs, followed by bone metastasis. Our study12 revealed that bone (32.1%) was the most 
common site of single organ metastasis in patients with resected stage I NSCLC, followed by 
the brain (29.2%). We further demonstrated that the patterns of distant metastasis included 
single and multiple organ metastases in approximately 64% and 36% of patients, 
respectively.  
The recurrence-free rate of stage I NSCLC (TNM 7) has also been reported in the 
literature.28,32,33  Maeda et al32,33 reported that the 5-year recurrence-free rate in patients 
with stage IA NSCLC (TNM 7) ranges between 84 to 87%. In another article by Maeda et 
al,28 they reported that 5-year recurrence-free rate in patients with stage I NSCLC (TNM 7) 
was 84.2%.  
4. Predictors of recurrence  
The predictors for recurrence in resected stage I NSCLC (TNM 6) has been well 
demonstrated in the literature.4,5,18,29 In the report by Martini et al,4 the factors having 
adverse effects on recurrence in resected stage I NSCLC included lesser resection than 
lobectomy, no lymph node dissection, T2 tumor, and greater tumor size. In the study by 
Harpole et al,5 the factors affecting early recurrence in resected stage I NSCLC included 
presence of symptoms, vascular invasion, visceral pleural invasion, and tumor size greater 
than 3 cm. Although both Martini et al4 and Harpole et al5 performed elegant analysis 
demonstrating the factors influencing tumor recurrence in resected stage I NSCLC, they did 
not analyze local recurrence and distant metastasis as separate end-points. Only few studies 
evaluated the risk factors for local recurrence and distant metastasis separately. Varlotto et 
al29 reported that local recurrence in resected NSCLC was associated with lymphatic or 
vascular invasion, the use of chemotherapy, and diabetes. Distant metastasis in resected 
NSCLC was significantly higher in patients with non-squamous cell histology, those 
undergoing pneumonectomy and those with more advanced TNM stage.29 In the report by 
Sawyer et al,18 the factors independently predicting local recurrence in resected stage I 
NSCLC included fewer than 15 lymph nodes dissected and T2 tumor. Tumor size greater 
than 5 cm and non-squamous histology independently predicted a poor distant metastasis-
free rate in resected stage I NSCLC.18 
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The predictors for recurrence in resected stage I NSCLC (TNM 7) has not been widely 
investigated in the literature. In the reports by Maeda et al,28,33 they demonstrated that 
histologic differentiation, intratumoral vascular invasion, and visceral of pleural invasion 
were significant predictors for recurrence in stage I NSCLC (TNM 7).  
5. Postrecurrence survival  
In our previous study,11 the 1- and 2-year post-recurrence survival rates for resected stage I 
NSCLC patients with local only recurrence were 48.7% and 17.6%, respectively. Tumor size 
and treatment for initial recurrence were significant predictors for post-recurrence survival 
in patients with local only recurrence in univariate analyses. The hazard of death was 
greater in patients with larger tumor size. Treatment for initial recurrence was still 
significant prognostic indicator in multivariate analysis. Patients underwent re-operation 
after local recurrence survived longer than those with chemotherapy or/and radiotherapy 
and those without treatment.  
For patients with single organ metastasis, the 1- and 2-year post-recurrence survival rates 
were 30.2% and 15.1%, respectively.12 The most common site of single organ metastasis was 
the bone, followed by the brain. Disease-free interval > 16 months and treatment for distant 
metastasis (including re-operation, chemotherapy and/or radiotherapy) were significant 
predictors of better post-recurrence survival in resected stage I NSCLC with single organ 
metastasis. Post-recurrence survival was not significantly different between single and 
multiple organ metastases groups of patients. Multiplicity of metastatic organ sites is not a 
significant prognostic factor in these patients. Yoshino and coworkers31 reported that the 2-
year survival rate of NSCLC patients with postoperative recurrence at distant organs was 
15.7 %. Their result is similar to that in our study.  
Surgical resection offers a good chance of cure for patients with stage I NSCLC.3,5,20 
However, the outcome of surgical treatment in resected stage I NSCLC after local recurrence 
have rarely been reported. Walsh et al34 reported that complete surgical resection or high-
dose radiotherapy with curative intent significantly prolonged post-recurrence survival in 
NSCLC. Sugimura et al10 demonstrated that whether surgery or combination chemotherapy 
with radiation significantly improved post-recurrence survival over both no treatment and 
radiation alone in resected NSCLC after local recurrence. Voltolini et al35 reported that 5-
year survival after re-operation for locally recurrent bronchogenic carcinoma was 15.5%. 
The 5-year post-recurrence survival in our patients undergoing re-operation after local 
recurrence was 15%. 
Treatment for recurrent NSCLC significantly prolongs overall survival and post-recurrence 
survival.10,34 Yoshino et al31 reported that patients who underwent metastatectomy for 
recurrence in distant organs had significantly longer survival while those with 
chemotherapy had marginally prolonged survival. Nakagawa et al7 reported that treatment 
for the initial recurrence prolonged survival in stage I NSCLC after recurrence. In our 
study,12 treatment for distant metastasis (including surgery and chemotherapy and/or 
radiotherapy) had a favorable survival in resected stage I NSCLC after distant metastasis 
than without treatment. There was no significant difference in post-recurrence survival 
between patients undergoing re-operation and those treated with chemotherapy and/or 
radiotherapy. However, there were two postoperative deaths due to respiratory failure after 
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pulmonary resection. If the two patients were excluded, patients undergoing re-operation 
had significantly better post-recurrence survival than those receiving chemotherapy and/or 
radiotherapy (P = 0.021). The differences of therapeutic effects of surgery and chemotherapy 
and/or radiotherapy need larger series for further investigation.  
Disease-free interval has also been shown to be a significant prognostic factor of post-
recurrence survival in NSCLC. Longer disease-free interval was associated as with better 
post-recurrence survival in NSCLC after complete pulmonary resection.10,34,36 Walsh et al34 
reported that disease-free interval greater than 12 months was a favorable predictor of post-
recurrence survival in NSCLC after complete resection. Our study12 showed that disease-
free interval > 16 months was a significant predictor for better post-recurrence survival in 
patients with stage I NSCLC after distant metastasis.  
Although some reports in the literature had tried to figure out the impact of specific 
distant metastatic organ sites on post-recurrence survival in resected NSCLC, small 
cohorts or mixtures with local and distant metastasis made it difficult to acquire definite 
results. Sugimura et al10 reported that initial recurrence confined to the lung was 
associated with better post-recurrence survival in resected NSCLC. Yoshino et al31 
demonstrated that intra-pulmonary metastasis was a favorable factor for postrecurrence 
survival of resected NSCLC, while bone metastasis was a marginally unfavorable factor. 
Liver metastasis has also been reported as a worse prognostic factor in NSCLC after 
recurrence.7,36 In our study, patients with distant metastases confined within the 
contralateral lung have significantly better post-recurrence survival than those with 
distant metastases outside the contralateral lung. We further showed that for patients 
with distant metastases outside the contralateral lung, those with bone metastasis had 
significantly worse post-recurrence survival. 
6. Conclusion 
Treatment for initial recurrence is a prognostic predictor for post-recurrence survival in 
resected stage I NSCLC with local recurrence. Longer disease-free interval and treatment for 
distant metastasis are indicators for better post-recurrence survival in resected stage I 
NSCLC with single organ metastasis. Complete surgical resection should be considered in 
selected candidates with resectable local recurrent disease. Aggressive treatment for distant 
metastasis in selected patients with longer disease-free interval may prolong the post-
recurrence survival.  
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